Use of Autologous Serum Eyedrops for the Treatment of Ocular Surface Disease: First US Experience in a Large Population as an Insurance-Covered Benefit
Open Access
- 1 December 2012
- journal article
- research article
- Published by American Medical Association (AMA) in American Journal of Ophthalmology
- Vol. 130 (12), 1612-1613
- https://doi.org/10.1001/archophthalmol.2012.1652
Abstract
Autologous serum eyedrops (ASEs) were first reported in the treatment of ocular disease in 1975 and have since been investigated in numerous ocular surface disorders.1 There are few studies from the United States, yet we know anecdotally that ASEs are used in tertiary care centers across the country.2 The lack of publicity about ASEs in the United States is, in large part, owing to unique barriers in implementing serum eyedrops as a standard treatment modality: laboratories must follow a manufacturing protocol in compliance with regulatory measures, patients must undergo phlebotomy, and patients must cover the cost. We report here a retrospective review of the first experience with ASEs in a large US patient population as an insurance-covered benefit.This publication has 6 references indexed in Scilit:
- Autologous Serum 50% Eyedrops in the Treatment of Persistent Corneal Epithelial DefectsCornea, 2009
- Autologous serum in the management of recalcitrant dry eye syndromeClinical & Experimental Ophthalmology, 2008
- The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control studyAmerican Journal of Ophthalmology, 2005
- Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface diseaseBritish Journal of Ophthalmology, 2004
- Controlled Study of the Use of Autologous Serum in Dry Eye PatientsCornea, 2001
- Clinical Experience With a Mobile Ocular Perfusion PumpAmerican Journal of Ophthalmology, 1975